Use of Upadacitinib in 16 Tofacitinib-refractory Ulcerative Colitis Patients: A Single-center Case 2Series.

Levine, Jake; McKibbin, Jey; Ham, Rebecca; Cohen-Mekelburg, Shirley; Bishu, Shrinivas; Tang, Kevin; Higgins, Peter D R; Berinstein, Jeffrey A

Levine, Jake; McKibbin, Jey; Ham, Rebecca; Cohen-Mekelburg, Shirley; Bishu, Shrinivas; Tang, Kevin; Higgins, Peter D R; Berinstein, Jeffrey A.

Afiliación

Levine J; Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA.
McKibbin J; Department of Pharmacy Services, Michigan Medicine, Ann Arbor, MI, USA.
Ham R; Department of Pharmacy Services, Michigan Medicine, Ann Arbor, MI, USA.
Cohen-Mekelburg S; Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA.
Bishu S; Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, MI, USA.
Tang K; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA.
Higgins PDR; VA Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI, USA.
Berinstein JA; Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA.

Inflamm Bowel Dis ; 2023 Dec 23.

Article en En | MEDLINE | ID: mdl-38142124

We present a case series of 16 patients with ulcerative colitis who received upadacitinib after failing tofacitinib. Five patients (36%) achieved steroid-free clinical remission. Five (62%) demonstrated endoscopic response, while 2 patients (25%) achieved endoscopic remission. Adverse events were low.

Palabras clave

tofacitinib; ulcerative colitis; upadacitinib

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Inflamm Bowel Dis Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google